Dr John David Kuhnlein, DO | |
1605 Se Delaware Ave Ste D, Ankeny, IA 50021-4595 | |
(515) 964-9003 | |
(515) 964-9032 |
Full Name | Dr John David Kuhnlein |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 1605 Se Delaware Ave Ste D, Ankeny, Iowa |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639210388 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 2446 (Iowa) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John David Kuhnlein, DO 1605 Se Delaware Ave Ste D, Ankeny, IA 50021-4595 Ph: (515) 964-9003 | Dr John David Kuhnlein, DO 1605 Se Delaware Ave Ste D, Ankeny, IA 50021-4595 Ph: (515) 964-9003 |
News Archive
ADVENTRX Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the proposed proprietary name "Exelbineâ„¢" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research "TransCure" have now found a new way to influence the endocannabinoid system.
FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr. Reddy's Laboratories Ltd. Vice-Chairman and CEO, G V Prasad today signed a Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
› Verified 6 days ago